pLL-EF1a-RFP-T2A-Blast Lenti-Labeler™ Lentivector Plasmid & Pre-packaged Virus

Reliably label cells with RFP driven by a moderate EF1α promoter (and with blasticidin selection) - great for tracking cells, HTS assays, and more
  • Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
  • Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
  • Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)

Products

Catalog Number Description Size Price Quantity Add to Cart
LL215PA-1 pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ plasmid) 10 µg $635
- +
LL215VA-1 pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ virus) >2x10^6 IFUs $635
- +

Overview

Overview

Reliable cell labeling, delivered

SBI’s family of Lenti-Labeler™ constructs facilitate a wide range of studies—including cell tracking, high-throughput assays, and more—by enabling efficient and reliable labeling of your cells. The pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ construct expresses RFP from the EF1α promoter, which delivers moderate expression in most cell types (including primary and stem cells), and co-expresses the blasticidin resistance gene for selection in vitro prior to in vivo use. Available as either fully propagatable, sequence-verified plasmid DNA (Cat.# LL215PA-1) or ready-to-transduce pre-packaged lentivirus (Cat.# LL215VA-1), SBI’s pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ is designed for reliability, so you can get to valuable insights faster.

pLL-EF1α-RFP-T2A-Blast Lenti-Labeler
  • Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
  • Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
  • Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)

While the pLL-EF1α-RFP-T2A-Blast Lenti-Labeler construct is compatible with most second and third generation packaging plasmid mixes, SBI recommends the use of pPACKH1 (Cat #LV500A-1) and TransDux MAX Transduction Reagent (Cat #LV860A-1) to achieve optimal virus titers and infection of target cells.

Find the right Lenti-Labeler construct for your studies

SBI offers Lenti-Labeler constructs with a range of selection markers, reporter genes, and two different promoters.

Table 1. Available Lenti-Labeler Constructs

Cat. #ConstructPromoterReporterSelection
LL100PA-1/LL100VA-1pLL-CMV-GFP-T2A-PuroCMV
GFPPuromycin
LL105PA-1/LL105VA-1pLL-CMV-GFP-T2A-Blast

CMVGFPBlasticidin
LL110PA-1/LL110VA-1pLL-CMV-RFP-T2A-PuroCMVRFPPuromycin
LL115PA-1/LL115VA-1pLL-CMV-RFP-T2A-BlastCMVRFPBlasticidin
LL120PA-1/LL120VA-1pLL-CMV-BFP-T2A-PuroCMVBFPPuromycin
LL125PA-1/LL125VA-1pLL-CMV-BFP-T2A-BlastCMVBFPBlasticidin
LL150PA-1/LL150VA-1pLL-CMV-Luciferase-T2A-PuroCMVLuciferasePuromycin
LL200PA-1/LL200VA-1pLL-EF1α-GFP-T2A-PuroEF1αGFPPuromycin
LL205PA-1/LL205VA-1pLL-EF1α-GFP-T2A-BlastEF1αGFPBlasticidin
LL210PA-1/LL210VA-1pLL-EF1α-RFP-T2A-PuroEF1αRFPPuromycin
LL215PA-1/LL215VA-1pLL-EF1α-RFP-T2A-BlastEF1αRFPBlasticidin
LL220PA-1/LL220VA-1pLL-EF1α-BFP-T2A-PuroEF1αBFPPuromycin
LL225PA-1/LL225VA-1pLL-EF1α-BFP-T2A-BlastEF1αBFPBlasticidin
LL250PA-1/LL250VA-1pLL-EF1α-Luciferase-T2A-PuroEF1αLuciferasePuromycin
LL300PA-1/LL300VA-1pLL-CMV-rFLuc-T2A-GFPCMVLuciferase & GFPN/A
LL310PA-1/LL310VA-1pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro CMVLuciferase & GFPPuromycin
LL320PA-1/LL320VA-1pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro CMVLuciferase & RFPPuromycin
LL410PA-1/LL410VA-1pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro EF1αLuciferase & GFPPuromycin
LL420PA-1/LL420VA-1pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro EF1αLuciferase & RFPPuromycin

References

How It Works

Supporting Data

Supporting Data

SBI’s Lenti-Labelers get your cells labeled efficiently, reliably

Lenti-Labeler

Figure 1. SBI Lenti-Labeler constructs reliably and efficiently label cells. Comparison of the number of fluorescently-labeled cells to the total number of cells seen in the corresponding phase contrast images reveals the high labeling efficiency of SBI’s Lenti-Labeler constructs.

FAQs

Resources

Citations

  • Abe, Y, et al. (2024) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Communications biology. 2024; 7(1):593. PM ID: 38760429
  • Reavis, HD, et al. (2024) Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI insight. 2024;. PM ID: 38271085
  • Chan, TS, et al. (2024) ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. Molecular oncology. 2024;. PM ID: 38279565
  • Kang, J, et al. (2024) Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing. Nature metabolism. 2024; 6(1):153-168. PM ID: 38243132
  • Wan, Q, et al. (2024) Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nature communications. 2024; 15(1):1442. PM ID: 38365882
  • Vilpreux, C, et al. (2024) Sperm motility in mice with Oligo-astheno-teratozoospermia restored by in vivo injection and electroporation of naked mRNA. eLife. 2024;. Link: eLife
  • Yu, BY, et al. (2024) Dimethyl α-Ketoglutarate Promotes the Synthesis of Collagen and Inhibits Metalloproteinases in HaCaT Cells. Biomolecules & therapeutics. 2024; 32(2):240-248. PM ID: 38296652
  • McCorkle, JR, et al. (2024) Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers. 2024; 16(7). PM ID: 38610999
  • Dufner, A, et al. (2024) Ubiquitin-specific protease 8 controls B cell proteostasis and cell survival in multiple myeloma. bioRxiv. 2024;. Link: bioRxiv
  • Uddin, M, et al. (2024) Advancement of Radiolabeled Exosomes in Brain Disorders. Exosomes Based Drug Delivery Strategies for Brain Disorders. 2024;:325-392. Link: Exosomes Based Drug Delivery Strategies for Brain Disorders
  • Lin, RZ, et al. (2024) Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024; 629(8012):660-668. PM ID: 38693258
  • Abdoul-Azize, S, et al. (2024) Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling. Nature communications. 2024; 15(1):4557. PM ID: 38811530
  • Tanaka, N, et al. (2023) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Research Square. 2023;. Link: Research Square
  • Celik, A, et al. (2023) Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023; 161:114524. PM ID: 36948134
  • Brightman, SE, et al. (2023) Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors. Nature immunology. 2023; 24(8):1345-1357. PM ID: 37400675
  • Jeon, HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer cell. 2023;. PM ID: 37451272
  • Yamada-Hunter, S, et al. (2023) Engineered CD47 protects T cells for enhanced antitumor immunity. bioRxiv. 2023;. Link: bioRxiv
  • Pearson, S, et al. (2023) Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PloS one. 2023; 18(5):e0286412. PM ID: 37253035
  • Campelo, SN, et al. (2023) High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas. Frontiers in oncology. 2023; 13:1171278. PM ID: 37213298
  • Sugita, M, et al. (2023) Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease. 2023; 14(5):305. PM ID: 37142568
pLL-EF1a-RFP-T2A-Blast Lenti-Labeler™ Lentivector Plasmid & Pre-packaged Virus $635.00

Products

Catalog Number Description Size Price Quantity Add to Cart
LL215PA-1 pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ plasmid) 10 µg $635
- +
LL215VA-1 pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ virus) >2x10^6 IFUs $635
- +

Overview

Overview

Reliable cell labeling, delivered

SBI’s family of Lenti-Labeler™ constructs facilitate a wide range of studies—including cell tracking, high-throughput assays, and more—by enabling efficient and reliable labeling of your cells. The pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ construct expresses RFP from the EF1α promoter, which delivers moderate expression in most cell types (including primary and stem cells), and co-expresses the blasticidin resistance gene for selection in vitro prior to in vivo use. Available as either fully propagatable, sequence-verified plasmid DNA (Cat.# LL215PA-1) or ready-to-transduce pre-packaged lentivirus (Cat.# LL215VA-1), SBI’s pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ is designed for reliability, so you can get to valuable insights faster.

pLL-EF1α-RFP-T2A-Blast Lenti-Labeler
  • Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
  • Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
  • Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)

While the pLL-EF1α-RFP-T2A-Blast Lenti-Labeler construct is compatible with most second and third generation packaging plasmid mixes, SBI recommends the use of pPACKH1 (Cat #LV500A-1) and TransDux MAX Transduction Reagent (Cat #LV860A-1) to achieve optimal virus titers and infection of target cells.

Find the right Lenti-Labeler construct for your studies

SBI offers Lenti-Labeler constructs with a range of selection markers, reporter genes, and two different promoters.

Table 1. Available Lenti-Labeler Constructs

Cat. #ConstructPromoterReporterSelection
LL100PA-1/LL100VA-1pLL-CMV-GFP-T2A-PuroCMV
GFPPuromycin
LL105PA-1/LL105VA-1pLL-CMV-GFP-T2A-Blast

CMVGFPBlasticidin
LL110PA-1/LL110VA-1pLL-CMV-RFP-T2A-PuroCMVRFPPuromycin
LL115PA-1/LL115VA-1pLL-CMV-RFP-T2A-BlastCMVRFPBlasticidin
LL120PA-1/LL120VA-1pLL-CMV-BFP-T2A-PuroCMVBFPPuromycin
LL125PA-1/LL125VA-1pLL-CMV-BFP-T2A-BlastCMVBFPBlasticidin
LL150PA-1/LL150VA-1pLL-CMV-Luciferase-T2A-PuroCMVLuciferasePuromycin
LL200PA-1/LL200VA-1pLL-EF1α-GFP-T2A-PuroEF1αGFPPuromycin
LL205PA-1/LL205VA-1pLL-EF1α-GFP-T2A-BlastEF1αGFPBlasticidin
LL210PA-1/LL210VA-1pLL-EF1α-RFP-T2A-PuroEF1αRFPPuromycin
LL215PA-1/LL215VA-1pLL-EF1α-RFP-T2A-BlastEF1αRFPBlasticidin
LL220PA-1/LL220VA-1pLL-EF1α-BFP-T2A-PuroEF1αBFPPuromycin
LL225PA-1/LL225VA-1pLL-EF1α-BFP-T2A-BlastEF1αBFPBlasticidin
LL250PA-1/LL250VA-1pLL-EF1α-Luciferase-T2A-PuroEF1αLuciferasePuromycin
LL300PA-1/LL300VA-1pLL-CMV-rFLuc-T2A-GFPCMVLuciferase & GFPN/A
LL310PA-1/LL310VA-1pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro CMVLuciferase & GFPPuromycin
LL320PA-1/LL320VA-1pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro CMVLuciferase & RFPPuromycin
LL410PA-1/LL410VA-1pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro EF1αLuciferase & GFPPuromycin
LL420PA-1/LL420VA-1pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro EF1αLuciferase & RFPPuromycin

References

How It Works

Supporting Data

Supporting Data

SBI’s Lenti-Labelers get your cells labeled efficiently, reliably

Lenti-Labeler

Figure 1. SBI Lenti-Labeler constructs reliably and efficiently label cells. Comparison of the number of fluorescently-labeled cells to the total number of cells seen in the corresponding phase contrast images reveals the high labeling efficiency of SBI’s Lenti-Labeler constructs.

FAQs

Citations

  • Abe, Y, et al. (2024) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Communications biology. 2024; 7(1):593. PM ID: 38760429
  • Reavis, HD, et al. (2024) Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI insight. 2024;. PM ID: 38271085
  • Chan, TS, et al. (2024) ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. Molecular oncology. 2024;. PM ID: 38279565
  • Kang, J, et al. (2024) Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing. Nature metabolism. 2024; 6(1):153-168. PM ID: 38243132
  • Wan, Q, et al. (2024) Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nature communications. 2024; 15(1):1442. PM ID: 38365882
  • Vilpreux, C, et al. (2024) Sperm motility in mice with Oligo-astheno-teratozoospermia restored by in vivo injection and electroporation of naked mRNA. eLife. 2024;. Link: eLife
  • Yu, BY, et al. (2024) Dimethyl α-Ketoglutarate Promotes the Synthesis of Collagen and Inhibits Metalloproteinases in HaCaT Cells. Biomolecules & therapeutics. 2024; 32(2):240-248. PM ID: 38296652
  • McCorkle, JR, et al. (2024) Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers. 2024; 16(7). PM ID: 38610999
  • Dufner, A, et al. (2024) Ubiquitin-specific protease 8 controls B cell proteostasis and cell survival in multiple myeloma. bioRxiv. 2024;. Link: bioRxiv
  • Uddin, M, et al. (2024) Advancement of Radiolabeled Exosomes in Brain Disorders. Exosomes Based Drug Delivery Strategies for Brain Disorders. 2024;:325-392. Link: Exosomes Based Drug Delivery Strategies for Brain Disorders
  • Lin, RZ, et al. (2024) Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024; 629(8012):660-668. PM ID: 38693258
  • Abdoul-Azize, S, et al. (2024) Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling. Nature communications. 2024; 15(1):4557. PM ID: 38811530
  • Tanaka, N, et al. (2023) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Research Square. 2023;. Link: Research Square
  • Celik, A, et al. (2023) Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023; 161:114524. PM ID: 36948134
  • Brightman, SE, et al. (2023) Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors. Nature immunology. 2023; 24(8):1345-1357. PM ID: 37400675
  • Jeon, HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer cell. 2023;. PM ID: 37451272
  • Yamada-Hunter, S, et al. (2023) Engineered CD47 protects T cells for enhanced antitumor immunity. bioRxiv. 2023;. Link: bioRxiv
  • Pearson, S, et al. (2023) Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PloS one. 2023; 18(5):e0286412. PM ID: 37253035
  • Campelo, SN, et al. (2023) High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas. Frontiers in oncology. 2023; 13:1171278. PM ID: 37213298
  • Sugita, M, et al. (2023) Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease. 2023; 14(5):305. PM ID: 37142568